Patient and Caregiver Site
Print Page

REGENCY evaluated the efficacy and safety of GAZYVA + ST* vs placebo + ST1

Quick Links

Study Design
Baseline Characteristics

REGENCY was a Phase III, randomized, double-blind, placebo-controlled, multicenter study1

Eligibility criteria1,21

  • Diagnosis of active ISN/RPS class III or IV ± class V lupus nephritis†
  • UPCR ≥1 g/g on a 24-hr collection
  • ≥1 dose of pulse methylprednisolone IV (≥250 mg) or equivalent, 6 months prior to or during screening

Randomized 1:1 (N=271).

Primary endpoint1

  • Complete renal response (CRR)

Select key secondary endpoints1,22

  • CRR§ with successful prednisone taper between Weeks 64 and 76 (≤7.5 mg/d)
  • Change in eGFR from baseline
  • Proportion of patients with renal-related event or death

Exploratory endpoints1,21

  • Components of CRR
  • CRR subgroup analysis
  • Time to renal-related event or death
  • Time to lupus nephritis flares between Weeks 24 and 76

*Standard therapy included MMF 2 g/d to 2.5 g/d and a tapering course of corticosteroids to a target dose of 5 mg/d.1
†Renal biopsy performed within 6 months before screening. Classified according to the ISN/RPS 2003 classification system for lupus nephritis.1
§CRR at Week 76: defined as UPCR <0.5 g/g; an eGFR ≥85% of baseline, with no occurrence of rescue therapy, treatment failure, death, or early study withdrawal through Week 76.1
eGFR=estimated glomerular filtrations rate; ISN/RPS=International Society of Nephrology/Renal Pathology Society; MMF=mycophenolate mofetil; ST=standard therapy; UPCR=urine protein-to-creatinine ratio.

The REGENCY study population was well-represented across key clinical characteristics1,21

A diverse and inclusive study population1,21

Select demographics and baseline characteristics combining both arms (N=271)

Age
Median (years) 31
Sex
Female 85%
Ethnicity/raceII
Hispanic or Latino 58%
White 48%
American Indian or Alaska Native 19%
Black or African American 15%
Asian 6%
Kidney biopsy class
Class III 39%
Class IV 61%
Concomitant class V 31%
eGFR at baseline (mL/min/1.73 m2)
Mean 102.3
(SD: ±30.8)
<90 29%
≥90 71%
24-hr UPCR at baseline (mg/mg)
Mean 3.3
(SD: ±2.9)
<3 58%
≥3 42%
Disease history
Newly diagnosed 42%
Prior history 58%
Median lupus nephritis duration if prior history (months) 37 (range:
0.4-330.4)
No prior advanced therapy 93%

IIEthnicity and race were not stated or were unknown for some patients. Patients could report multiple races.22
Prior advanced therapies had to be discontinued >2 months before or during study screening.1
SD=standard deviation.

Contact your representative
Contact your representative

Interested in more information about GAZYVA?

Contact Us
NEXT: Primary Endpoint

Important Safety Information and Indication

Indication

GAZYVA® (obinutuzumab) is indicated for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.

BOXED WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

  • Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV-positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation
  • Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving GAZYVA

Contraindications

  • GAZYVA is contraindicated in patients with known hypersensitivity reactions (eg, anaphylaxis) to obinutuzumab or to any of the excipients, or serum sickness with prior obinutuzumab use

Warnings and Precautions

Hepatitis B Virus Reactivation
  • GAZYVA can cause hepatitis B virus (HBV) reactivation. HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with anti-CD20 antibodies, including GAZYVA. HBV reactivation has been reported in patients who are hepatitis B surface antigen (HBsAg) positive and in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation has also occurred in patients who appear to have resolved hepatitis B infection (ie, HBsAg negative, anti-HBc positive, and hepatitis B surface antibody [anti-HBs] positive)
  • HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level, or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, ie, increase in transaminase levels and in severe cases, increase in bilirubin levels, liver failure, and death
  • Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with GAZYVA. For patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult healthcare providers with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy
  • Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with GAZYVA
  • In patients who develop reactivation of HBV while receiving GAZYVA, immediately discontinue GAZYVA and any concomitant chemotherapy and institute appropriate treatment. Resumption of GAZYVA in patients whose HBV reactivation resolves should be discussed with healthcare providers with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming GAZYVA in patients who develop HBV reactivation
Progressive Multifocal Leukoencephalopathy (PML)
  • John Cunningham (JC) virus infection resulting in PML, which can be fatal, occurred in patients treated with GAZYVA in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Consider the diagnosis of PML in any patient presenting with new onset or changes to, preexisting neurologic manifestations. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture. Discontinue GAZYVA therapy and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML
Infusion-Related Reactions
  • GAZYVA can cause severe and life-threatening infusion-related reactions (IRRs)
  • In patients with LN, IRRs occurred predominantly during infusion of the first 1,000 mg. IRRs were generally mild to moderate and could be managed by slowing or temporarily halting the infusion. Severe and life-threatening IRRs requiring symptomatic treatment were also reported. The most common IRR signs/symptoms reported in the REGENCY study included headache, nausea, and vomiting. In the NOBILITY study, the most common IRR symptoms were pyrexia and tachycardia
  • Premedicate patients with acetaminophen, an antihistamine, and a glucocorticoid. Closely monitor patients during the entire infusion. Reduce infusion rate, interrupt infusion, or permanently discontinue GAZYVA for IRRs based on severity. Institute medical management (eg, glucocorticoids, epinephrine, bronchodilators, and/or oxygen) for IRRs as needed
  • For patients with preexisting cardiac or pulmonary conditions, monitor more frequently throughout the infusion and the post-infusion period, since they may be at greater risk of experiencing more severe reactions. Hypotension may occur as part of the IRR to GAZYVA. Consider withholding antihypertensive treatments for 12 hours prior to, during each GAZYVA infusion, and for the first hour after administration until blood pressure is stable. For patients at increased risk of hypertensive crisis, consider the benefits versus the risks of withholding their antihypertensive medication
Hypersensitivity Reactions Including Serum Sickness
  • Hypersensitivity reactions have been reported in patients treated with GAZYVA. Signs of immediate-onset hypersensitivity included dyspnea, bronchospasm, hypotension, urticaria, and tachycardia. Late-onset hypersensitivity diagnosed as serum sickness has also been reported, with symptoms that include chest pain, diffuse arthralgia, and fever. Hypersensitivity reactions may be difficult to clinically distinguish from IRRs. However, hypersensitivity very rarely occurs with the first infusion and, when observed, often occurs after previous exposure
  • If a hypersensitivity reaction is suspected during or after an infusion, stop the infusion and permanently discontinue treatment. GAZYVA is contraindicated in patients with known hypersensitivity reactions to GAZYVA, including serum sickness with prior GAZYVA use
Serious, Including Fatal, Infections
  • Fatal and serious bacterial, fungal, and new or reactivated viral infections can occur during and following GAZYVA therapy
  • In the pooled double-blind periods of REGENCY (Week 76) and NOBILITY (Week 52), the incidence of Grade 3-5 infections was 11% (22/200) in patients treated with GAZYVA and standard therapy compared to 9% (18/193) in patients receiving placebo and standard therapy, corresponding to an exposure-adjusted incidence rate (EAIR) of 8.9 and 7.9 per 100 patient years, respectively. The incidence of fatal infections was 1% (2/200) in patients treated with GAZYVA and 0.5% (1/193) in patients receiving placebo, corresponding to an EAIR of 0.8 and 0.4 per 100 patient years, respectively
  • In 40 patients who crossed-over from placebo to GAZYVA and standard therapy at Week 76 in the REGENCY study, and patients who continued treatment with GAZYVA and standard therapy, including additional treatment after Week 76, the EAIR of Grade 3-5 infections for the GAZYVA arm was 9.0 per 100 patient years while the EAIR of fatal infections for the GAZYVA arm was 1.8 per 100 patient years
  • Do not administer GAZYVA to patients with an active infection. Patients with a history of recurring or chronic infections may be at increased risk of infection. In patients who develop a serious infection while receiving GAZYVA, immediately discontinue GAZYVA and institute appropriate treatment. Consider the risk and benefit of resuming treatment with GAZYVA following resolution of serious infections
Neutropenia
  • Severe and life-threatening neutropenia, including febrile neutropenia, has been reported during treatment with GAZYVA. Monitor patients with Grade 3 to 4 neutropenia frequently with regular laboratory tests until resolution. Anticipate, evaluate, and treat any symptoms or signs of developing infection. Consider dose delays for Grade 3 or 4 neutropenia. Consider administration of granulocyte colony-stimulating factors (GCSFs) in patients with Grade 3 or 4 neutropenia
  • Neutropenia can also be of late onset (occurring more than 28 days after completion of treatment) and/or prolonged (lasting longer than 28 days)
  • Patients with severe and long-lasting (>1 week) neutropenia are strongly recommended to receive antimicrobial prophylaxis until resolution of neutropenia to Grade 1 or 2. Consider antiviral and antifungal prophylaxis
Thrombocytopenia
  • Severe and life-threatening thrombocytopenia has been reported during treatment with GAZYVA in combination with chemotherapy. Fatal hemorrhagic events have been reported in patients with CLL treated with GAZYVA in combination with chemotherapy
  • Monitor patients frequently for thrombocytopenia and hemorrhagic events, and if clinically indicated, evaluate laboratory coagulation parameters. In patients with Grade 3 or 4 thrombocytopenia, monitor platelet counts more frequently until resolution and consider dose delays of GAZYVA and chemotherapy or dose reductions of chemotherapy. Transfusion of blood products (ie, platelet transfusion) may be necessary. Consider withholding concomitant medications that may increase bleeding risk (platelet inhibitors or anticoagulants), especially during the first cycle
Disseminated Intravascular Coagulation (DIC)
  • Fatal and severe DIC has been reported in patients receiving GAZYVA for CLL and NHL. The majority of DIC cases have involved changes in platelets and laboratory coagulation parameters following the first infusion, with spontaneous resolution usually occurring by Day 8. In some cases, DIC was associated with IRRs
  • In patients with suspected DIC, evaluate potential causes and monitor coagulation parameters, platelet counts, and for signs and symptoms of bleeding or thrombosis. Manage according to standard guidelines for DIC. Supportive care, including transfusion of blood products and other medical management, may be necessary
Immunization
  • The safety and efficacy of immunization with live or attenuated viral vaccines during or following GAZYVA therapy have not been studied. Immunization with live virus vaccines is not recommended during treatment with GAZYVA and until B-cell recovery
Embryo-Fetal Toxicity
  • Based on its mechanism of action and findings in animals, GAZYVA can cause B-cell depletion in infants exposed to obinutuzumab in utero. Advise pregnant women of the potential risk to the fetus. Mothers who have been exposed to GAZYVA during pregnancy should discuss the safety and timing of live virus vaccinations for their infants with their child’s healthcare providers. Advise females of reproductive potential to use effective contraception while receiving GAZYVA and for 6 months after the last dose
Lactation
  • Human IgG is known to be present in human milk. Because of the potential of serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with GAZYVA and for 6 months after the last dose

Additional Important Safety Information

  • The most common adverse reactions (incidence ≥5%) observed in patients with LN in the GAZYVA arm were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion-related reactions, and neutropenia
  • The most common serious adverse reactions in the GAZYVA arm were: COVID-19 (5.5%), pneumonia (4.5%), neutropenia (3.5%), urinary tract infections (2.5%), and infusion-related reactions (0.5%). No serious adverse reactions were reported for bronchitis, herpes simplex and upper respiratory tract infections. Two fatal adverse reactions of COVID-19 were reported in the GAZYVA arm

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see the full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.

    • GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2025.

      GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2025.

    • Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. Published online October 16, 2025.
      doi:10.1016/j.ard.2025.09.007

      Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. Published online October 16, 2025.
      doi:10.1016/j.ard.2025.09.007

    • Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi:10.1038/s41572​-019​-0141​-9

      Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi:10.1038/s41572​-019​-0141​-9

    • Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011​-1020. doi:10.1177/0961203320932219

      Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011​-1020. doi:10.1177/0961203320932219

    • Bastian HM, Roseman JM, McGwin G Jr, et al; LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152-160. doi:10.1191/0961203302lu158oa

      Bastian HM, Roseman JM, McGwin G Jr, et al; LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152-160. doi:10.1191/0961203302lu158oa

    • Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. doi:10.1053/j.ajkd.2019.10.017

      Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. doi:10.1053/j.ajkd.2019.10.017

    • Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kidney Int. 2016;90(3):487-492. doi:10.1016/j.kint.2016.03.042

      Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kidney Int. 2016;90(3):487-492. doi:10.1016/j.kint.2016.03.042

    • Urowitz M, Georgiou ME, Touma Z, et al. Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort. Lupus Sci Med. 2024;11(2):e001264. doi:10.1136/lupus-2024-001264

      Urowitz M, Georgiou ME, Touma Z, et al. Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort. Lupus Sci Med. 2024;11(2):e001264. doi:10.1136/lupus-2024-001264

    • Yap DYH, Xu X, Juliao PC, et al. Long-term kidney outcome of lupus nephritis by renal response status. Kidney Int Rep. 2024;9(12):3532-3541. doi:10.1016/j.ekir.2024.09.028

      Yap DYH, Xu X, Juliao PC, et al. Long-term kidney outcome of lupus nephritis by renal response status. Kidney Int Rep. 2024;9(12):3532-3541. doi:10.1016/j.ekir.2024.09.028

    • Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol. 2018;45(5):671-677. doi:10.3899/jrheum.161554

      Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol. 2018;45(5):671-677. doi:10.3899/jrheum.161554

    • Ali AY, Abdelaziz TS, Behiry ME. The prevalence and causes of non-adherence to immunosuppressive medications in patients with lupus nephritis flares. Curr Rheumatol Rev. 2020;16(3):245-248. doi:10.2174/1573397115666190626111847

      Ali AY, Abdelaziz TS, Behiry ME. The prevalence and causes of non-adherence to immunosuppressive medications in patients with lupus nephritis flares. Curr Rheumatol Rev. 2020;16(3):245-248. doi:10.2174/1573397115666190626111847

    • Mehat P, Atiquzzaman M, Esdaile JM, Aviña-Zubieta A, De Vera MA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2017;69(11):1706-1713. doi:10.1002/acr.23191

      Mehat P, Atiquzzaman M, Esdaile JM, Aviña-Zubieta A, De Vera MA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2017;69(11):1706-1713. doi:10.1002/acr.23191

    • Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025;77(9):1045-1065. doi:10.1002/acr.25528

      Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025;77(9):1045-1065. doi:10.1002/acr.25528

    • Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(suppl 1):S1-S69. doi:10.1016/j.kint.2023.09.002

      Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(suppl 1):S1-S69. doi:10.1016/j.kint.2023.09.002

    • Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi:10.2215/CJN.01070118. Published correction appears in Clin J Am Soc Nephrol. 2019;14(1):111. doi:10.2215/CJN.12621018

      Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi:10.2215/CJN.01070118. Published correction appears in Clin J Am Soc Nephrol. 2019;14(1):111. doi:10.2215/CJN.12621018

    • Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357-1366. doi:10.1681/ASN.2013010026

      Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357-1366. doi:10.1681/ASN.2013010026

    • Thompson JC, Mahajan A, Scott DA, Gairy K. The economic burden of lupus nephritis: a systematic literature review. Rheumatol Ther. 2022;9(1):25-47. doi:10.1007/s40744-021-00368-y

      Thompson JC, Mahajan A, Scott DA, Gairy K. The economic burden of lupus nephritis: a systematic literature review. Rheumatol Ther. 2022;9(1):25-47. doi:10.1007/s40744-021-00368-y

    • Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042. doi:10.1158/1535-7163.MCT-12-1182

      Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042. doi:10.1158/1535-7163.MCT-12-1182

    • Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22-33. doi:10.4161/mabs.22771

      Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22-33. doi:10.4161/mabs.22771

    • Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393​-4402. doi:10.1182/blood-2009-06-225979

      Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393​-4402. doi:10.1182/blood-2009-06-225979

    • Data on file. Genentech, Inc.

      Data on file. Genentech, Inc.

    • Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471​-1483. doi:10.1056/NEJMoa2410965

      Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471​-1483. doi:10.1056/NEJMoa2410965

    • Data on file. REGENCY steroid taper plots. Genentech, Inc.

      Data on file. REGENCY steroid taper plots. Genentech, Inc.

    • Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107. doi:10.1136/annrheumdis-2021​-220920

      Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107. doi:10.1136/annrheumdis-2021​-220920

    • Low blood pressure (hypotension). Mayo Clinic. Published June 13, 2024. Accessed July 18, 2025. https://www.mayoclinic.org/diseases-conditions/low-blood-pressure/symptoms-causes/syc-20355465

      Low blood pressure (hypotension). Mayo Clinic. Published June 13, 2024. Accessed July 18, 2025. https://www.mayoclinic.org/diseases-conditions/low-blood-pressure/symptoms-causes/syc-20355465

    • Costedoat-Chalumeau N, Houssiau FA. Improving medication adherence in patients with lupus nephritis. Kidney Int. 2021;99(2):285-287. doi:10.1016/j.kint.2020.10.037

      Costedoat-Chalumeau N, Houssiau FA. Improving medication adherence in patients with lupus nephritis. Kidney Int. 2021;99(2):285-287. doi:10.1016/j.kint.2020.10.037

    • Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. doi:10.1056/NEJMra050100

      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. doi:10.1056/NEJMra050100

    • Rovin BH, Pendergraft WF III, Lightstone L, et al. Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: a pre-specified exploratory analysis of the REGENCY study. Poster presented at: EULAR 2025 Congress; June 11-14, 2025; Barcelona Spain.

      Rovin BH, Pendergraft WF III, Lightstone L, et al. Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: a pre-specified exploratory analysis of the REGENCY study. Poster presented at: EULAR 2025 Congress; June 11-14, 2025; Barcelona Spain.

    • Parodis I, Depascale R, Doria A, Anders HJ. When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients? Autoimmun Rev. 2024;23(1):103418. doi:10.1016/j.autrev.2023.103418

      Parodis I, Depascale R, Doria A, Anders HJ. When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients? Autoimmun Rev. 2024;23(1):103418. doi:10.1016/j.autrev.2023.103418

    • Data on file. CSR CA41705 REGENCY Pharmacy Manual. Genentech, Inc.

       

      Data on file. CSR CA41705 REGENCY Pharmacy Manual. Genentech, Inc.